BioXcel Therapeutics Amends Credit Agreement, Receives $1.25M Term Loan

What Happened

• BioXcel Therapeutics filed an 8-K reporting that on August 24, 2026 it entered into a Fourteenth Amendment to its Credit Agreement and Guaranty with its lenders and Oaktree Fund Administration LLC as administrative agent. Under the amendment the lenders provided additional term loans totaling $1,250,000 (the “Amendment No. 14 Term Loans”); the Company paid a $250,000 upfront fee (20% of the loan amount).
• Aside from the upfront fee, the new term loans carry the same economic and other terms as the preexisting loans under the Credit Agreement.

Key Details

• Date of amendment: August 24, 2026.
• New borrowing: $1,250,000 principal; upfront fee: $250,000 (20%).
• Covenant change: minimum cash liquidity requirement reduced from $3.0 million to $250,000.
• Deadline/requirement: by on or prior to August 31, 2026 (extended from August 28), the Company must enter into definitive agreements for transactions that either (A) repay all obligations under the Credit Agreement or (B) provide an alternative capital solution acceptable to the lenders.
• Other changes: certain covenants and thresholds were tightened to limit prior flexibility around out-licensing of IP and asset sales.

Why It Matters

• The company obtained short-term additional funding but at a high upfront cost (20%), increasing near-term cash obligations.
• Lowering the minimum liquidity covenant to $250K gives the company leeway to operate with much less cash on hand but also signals tighter lender control and closer scrutiny.
• The requirement to secure a repayment or alternative capital solution by Aug 31, 2026 is a near-term milestone investors should watch; failure to meet acceptable terms could affect the company’s credit standing or trigger further lender actions.
• Changes that restrict out-licensing and asset sales reduce management’s flexibility to generate cash from assets, which could affect future financing or restructuring options.